Seeking Alpha
19 Sept 2025, 15:03 UTC · 51w ago
Verdict
Headline takes no side. We score KURA +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA decision for lead asset Ziftomenib in AML is expected in late 2025.
More positive than 98% of claims this week
Kura Oncology has entered a strategic partnership with Kyowa Kirin providing non-dilutive funding and risk-sharing.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Kura Oncology maintains a strong cash position and a diversified pipeline.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company has a Buy rating, a strong cash position, and a robust pipeline with a potential commercial inflection point.
More positive than 65% of ticker scores this week
Kyowa Kirin is mentioned as a strategic partner in a deal that provides global reach and risk-sharing.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
—
No price for KURA right now — the quote feed didn't answer.
KURA chart →
